Cell Viability Assays Market Analysis by Product (Consumables, and Instrument); and by Application (Drug Discovery & Development, and Stem Cell Research) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2035
Buy Now Report ID: 4785 | Published Date: Apr 05, 2023
The global cell viability assays market size is estimated to reach ~USD 17.68 Billion by the end of 2035 by growing at a CAGR of ~11.40% over the forecast period, i.e., 2023 – 2035. In addition to this, in the year 2022, the market size of cell viability assays was ~USD 4.84 Billion. The growth of the market can be attributed to growing focus in developing cell therapy for the treatment of covid19 and its growing approval. For instance, Calidi Biotherapeutics Inc. announced in 2020 that the Food and Drug Administration had approved the Investigational New Drug (IND) application submitted by its partner, Personalized Stem Cells Inc. (PSC), for the use of stem cell therapy to treat COVID-19 and pneumonia patients. Given that cell viability assays are mostly used to test how well cells react to a drug or chemical agent, the market for these tests is anticipated to soar throughout the forecast year as a result of an increase in the use of cell-based therapies.
Moreover, there has been surge in investment and funding for cell based research. For instance, the California Center for Regenerative Medicine (CIRM) stated in May 2022 it was going to invest about USD 10 million in a cell therapy clinical trial to aid patients with throat cancer in recovering from the terrible radiation therapy side effects. Therefore, this factor is further estimated to drive the market growth over the forecast period. Additionally, the need for cell viability assays has also increased as a result of growing knowledge about stem cell therapies among developing nation, and this is anticipated to continue driving market revenue growth throughout the forecast period.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~11.40% |
|
Base Year Market Size (2022) |
~ USD 4.84 Billion |
|
Forecast Year Market Size (2035) |
~ USD 17.68 Billion |
|
Regional Scope |
|
Growth Drivers
According to the World Health Organization, one in six persons on the planet would be 60 years of age or older by the year 2030. By 2022, there was estimated to be 1.4 billion people, up from 1 billion in 2020, who are 60 years of age or older. Tissues are composed primarily of cells. Aging causes alterations in all cells. They enlarge and lose their capacity for division and multiplication. In addition to other modifications, the cell's inside also contains more pigments and fatty compounds (lipids). Many cells stop working properly or start working in an unnatural way with the growing age. Hence, the demand for cell viability assays is estimated to increase.
According to World Health Organization, almost 10 million deaths, or roughly one in six deaths, would be caused by cancer in 2020, making it the top cause of death globally.
Over the past 50 years, 12 lakh transplants have been carried out using stem cells worldwide. There are already around 49,000 transplants carried out each year, and the number is increasing.
To better the lives of Australians, the Morrison Government funded about USD 179 million in ground-breaking medical research initiatives across Australia in June 2021. Approximately 105 medical research projects were anticipated to get financing under the governments Medical Research Future Fund about USD 19 billion in order to enhance health outcomes, especially for Australians with cancer, dementia, brain injuries, heart difficulties, neurofibromatosis, and many other conditions.
According to the CDC, between 2010 and 2020, flu-related illnesses ranged from 9 million to 41 million, hospitalizations ranged from 140,000 to 710,000, and fatalities ranged from 12,000 to 52,000 in the United States. Hence, the demand for cell viability assays is rising.
Challenges
The global cell viability assays market is segmented and analyzed for demand and supply by application into drug discovery & development, and stem cell research. Amongst which, the stem cell research segment is anticipated to have a significant growth over the forecast period. The growth of the segment can be attributed to growing investment in stem cell research. It was estimated that the Novo Nordisk Foundation would invest up to USD 340 million over ten years in the development of a global stem cell research facility in 2022. Moreover, growing prevalence of cardiovascular disease is also estimated to boost the growth segment. Usually, problems with the blood vessels cause cardiovascular disease. New blood vessels are produced using stem cells that look and operate just as conventional blood vessels. Stem cells from the bank could help individuals manage conditions such as vascular and cardiovascular disease since they are able to repair or regenerate a variety of human tissues. Also, the rise in diabetes I prevalence is estimated to boost the segment growth. Diabetes type I, which is brought on by malfunctioning pancreatic cells, exhibits symptoms such as low levels of insulin or insufficient production of the hormone in the body. Pancreatic stem cells could be transplanted into persons with type 1 diabetes using preserved stem cells. These cells may be able to repair immune-system-damaged insulin-producing cells in patients, resolving the problem. Hence with their growing productivity, the research on stem cell has been growing.
The global cell viability assays market is also segmented and analyzed for demand and supply by product into consumables, and instrument. Amongst which, the consumables segment is anticipated to have the significant growth over the forecast period, backed by applications of consumables in diagnostic, stem cell, and pharmaceutical and biopharmaceutical research. Also, a number of market participants are providing a large selection of non-toxic, ready-to-use, and high-quality results-immediate cell viability assay reagents. Hence, this factor is estimated to boost the growth of the segment.
Our in-depth analysis of the global cell viability assays market includes the following segments:
|
By Product |
|
|
By Application |
|
The market share of cell viability assays in North America, amongst the market in all the other regions, is projected to have the highest growth, backed by growing cases of cancer, and infrastructure for clinical and laboratory research that is of a high caliber which exists in North America. A projected 1,806,590 new instances of cancer were identified in the US in 2020, while 606,520 people passed away from the illness. Hence, the demand for cell based therapies is estimated to boost which would drive the market growth. The need for cell viability assays has increased as a result of expanding research and development capabilities along with increasing spending to build healthcare infrastructure. Another indirect factor affecting the cell viability assays market growth is the growing elderly population along with changing lifestyles. The typical American diet is high in added sugars, processed carbohydrates, solid fat calories, excess salt, and saturated fat. Moreover, the consumption of alcohol is also high in this region which has led to an unhealthy lifestyle among people. Therefore, the prevalence of obesity is high in this region which has further influenced growth of various cardiovascular disease. Therefore, the market is estimated to grow owing to this factor.
The Asia Pacific cell viability assays market is estimated to be the second largest, to have the highest growth. The growth of the market can be attributed to growing government initiatives in order to make people aware about the growing prevalence of cancer and various cell therapies available for the same. Moreover, government in this region is also investing heavily on R&D. However, various private sectors are also investing in cell therapies such as stem cell therapy. Hence, these factors are estimated to boost the growth of the market in this region. Additionally, growing demand for biopharmaceuticals and the existence of cutting-edge research and healthcare infrastructure in the region is also expected to drive market growth.
Additionally, the market in Europe region is also expected to have the significant growth over the forecast period, backed growing prevalence of chronic disease. In Europe, chronic diseases are the main contributor to morbidity and mortality. Although, it is commonly known that Europe's population is ageing, chronic diseases impact a variety of age groups in addition to seniors. A growing number of adults in their 20s and 30s are dealing with chronic health issues. Chronic illnesses have raised absenteeism, early retirement, and disability while lowering pay and productivity in Europe. The growing influence on health and how they affect the individual personal life owing to chronic illnesses have created both unique challenges and transformational opportunities. Hence, this factor is estimated to drive the market for cell viability assays in Europe region.
The Improved Applied Biosystems HIV-1 Genotyping Kit was released by Thermo Fisher Scientific, Inc. The new kit complements the previously released Applied Biosystems MagMAX Viral/Pathogen Nucleic Acid Isolation Kit for HIV-1 Blood Spots. With the aid of this device, labs may monitor HIV mutations to antiretroviral treatment inhibitors using a cutting-edge method for drug resistance surveillance.
The BD Rhapsody TCR/BCR Multiomic Assay, a cutting-edge set of reagents that enables researchers to more easily and thoroughly analyse crucial immune system cells, was released by BD (Becton, Dickinson and Company), a leading global medical technology company. This assay would then be used to advance research on autoimmune disorders, immuno-oncology, and infectious diseases.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: The major factors driving the growth of the market are growing geriatric population, rise in prevalence of cancer, surge in need for stem cell transplant, and others.
Ans: The market size of cell viability is anticipated to attain a CAGR of ~11.40% over the forecast period, i.e., 2023 – 2035.
Ans: Shortage of technical specialists and professionals to sun instruments, high cost of cell viability assays, and lack of awareness among people are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Ans: The major players in the market are Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Bio-Rad Laboratories Inc., Merck KGaA, and more.
Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by product, application and by region.
Ans: The stem cell research segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
